Pyrrolyl-hydroxamates having the structural formula (I): and pharmaceutically acceptable salts thereof, wherein R, R1, R2, X and n are defined as in the description, in a form selected from the group consisting of: equimolar zinc saturated form (100% saturation), 1% to 90% zinc saturated form and zinc-free form, for use in the prevention and/or treatment of bacterial infections.